Patents by Inventor Rita Steeves

Rita Steeves has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240366720
    Abstract: In some aspects, the invention teaches pharmaceutical compositions that include a TGF-? ligand trap, and methods of using a TGF-? ligand trap to treat, prevent, or reduce the progression rate of pulmonary hypertension (PH). The invention also provides methods of using a TGF-? ligand trap to treat, prevent, or reduce the progression rate of a variety of conditions including, but not limited to, pulmonary vascular remodeling, pulmonary fibrosis, right ventricular hypertrophy, diseases associated with excessive TGF-? signaling, diseases associated with excessive GDF15 signaling, and diseases associated with excessive PAI-1 signaling. The invention further provides methods of using a TGF-? ligand trap to reduce right ventricular systolic pressure in a subject.
    Type: Application
    Filed: March 1, 2024
    Publication date: November 7, 2024
    Applicants: THE BRIGHAM AND WOMEN'S HOSPITAL, INC., ACCELERON PHARMA INC.
    Inventors: Paul B. YU, Asya GRINBERG, Dianne S. SAKO, Roselyne CASTONGUAY, Rita STEEVES, Ravindra KUMAR
  • Patent number: 11951156
    Abstract: In some aspects, the invention teaches pharmaceutical compositions that include a TGF-? ligand trap, and methods of using a TGF-? ligand trap to treat, prevent, or reduce the progression rate of pulmonary hypertension (PH). The invention also provides methods of using a TGF-? ligand trap to treat, prevent, or reduce the progression rate of a variety of conditions including, but not limited to, pulmonary vascular remodeling, pulmonary fibrosis, right ventricular hypertrophy, diseases associated with excessive TGF-? signaling, diseases associated with excessive GDF15 signaling, and diseases associated with excessive PAI-1 signaling. The invention further provides methods of using a TGF-? ligand trap to reduce right ventricular systolic pressure in a subject.
    Type: Grant
    Filed: April 17, 2020
    Date of Patent: April 9, 2024
    Assignees: THE BRIGHAM AND WOMEN'S HOSPITAL, INC., ACCELERON PHARMA, INC.
    Inventors: Paul B. Yu, Asya Grinberg, Dianne S. Sako, Roselyne Castonguay, Rita Steeves, Ravindra Kumar
  • Publication number: 20210230252
    Abstract: In certain aspects, the present disclosure relates to polypeptides comprising a truncated, ligand-binding portion of the extracellular domain of T?RII polypeptide useful to selectively antagonize a T?RII ligand. The disclosure further provides compositions and methods for use in treating or preventing TGF? associated disorders.
    Type: Application
    Filed: April 13, 2021
    Publication date: July 29, 2021
    Inventors: Ravindra Kumar, Asya Grinberg, Dianne S. Sako, Roselyne Castonguay, Rita Steeves
  • Patent number: 11008377
    Abstract: In certain aspects, the present disclosure relates to polypeptides comprising a truncated, ligand-binding portion of the extracellular domain of T?RII polypeptide useful to selectively antagonize a T?RII ligand. The disclosure further provides compositions and methods for use in treating or preventing TGF? associated disorders.
    Type: Grant
    Filed: January 30, 2020
    Date of Patent: May 18, 2021
    Assignee: ACCELERON PHARMA INC.
    Inventors: Ravindra Kumar, Asya Grinberg, Dianne S. Sako, Roselyne Castonguay, Rita Steeves
  • Patent number: 10981973
    Abstract: In certain aspects, the present disclosure relates to polypeptides comprising a truncated, ligand-binding portion of the extracellular domain of T?RII polypeptide useful to selectively antagonize a T?RII ligand. The disclosure further provides compositions and methods for use in treating or preventing TGF? associated disorders.
    Type: Grant
    Filed: April 24, 2019
    Date of Patent: April 20, 2021
    Assignee: ACCELERON PHARMA INC.
    Inventors: Ravindra Kumar, Asya Grinberg, Dianne S. Sako, Roselyne Castonguay, Rita Steeves
  • Publication number: 20200323955
    Abstract: In some aspects, the invention teaches pharmaceutical compositions that include a TGF-? ligand trap, and methods of using a TGF-? ligand trap to treat, prevent, or reduce the progression rate of pulmonary hypertension (PH). The invention also provides methods of using a TGF-? ligand trap to treat, prevent, or reduce the progression rate of a variety of conditions including, but not limited to, pulmonary vascular remodeling, pulmonary fibrosis, right ventricular hypertrophy, diseases associated with excessive TGF-? signaling, diseases associated with excessive GDF15 signaling, and diseases associated with excessive PAI-1 signaling. The invention further provides methods of using a TGF-? ligand trap to reduce right ventricular systolic pressure in a subject.
    Type: Application
    Filed: April 17, 2020
    Publication date: October 15, 2020
    Applicants: THE BRIGHAM AND WOMEN'S HOSPITAL, INC., ACCELERON PHARMA INC.
    Inventors: Paul B. YU, Asya GRINBERG, Dianne S. SAKO, Roselyne CASTONGUAY, Rita STEEVES, Ravindra KUMAR
  • Patent number: 10745462
    Abstract: In certain aspects, the present disclosure relates to polypeptides comprising a truncated, ligand-binding portion of the extracellular domain of T?RII polypeptide useful to selectively antagonize a T?RII ligand. The disclosure further provides compositions and methods for use in treating or preventing TGF? associated disorders.
    Type: Grant
    Filed: April 24, 2019
    Date of Patent: August 18, 2020
    Assignee: ACCELERON PHARMA INC.
    Inventors: Ravindra Kumar, Asya Grinberg, Dianne S. Sako, Roselyne Castonguay, Rita Steeves
  • Patent number: 10682392
    Abstract: In some aspects, the invention teaches pharmaceutical compositions that include a TGF-beta ligand trap, and methods of using a TGF-beta ligand trap to treat, prevent, or reduce the progression rate of pulmonary hypertension (PH). The invention also provides methods of using a TGF-beta ligand trap to treat, prevent, or reduce the progression rate of a variety of conditions including, but not limited to, pulmonary vascular remodeling, pulmonary fibrosis, right ventricular hypertrophy, diseases associated with excessive TGF-beta signaling, diseases associated with excessive GDF15 signaling, and diseases associated with excessive PAI-1 signaling. The invention further provides methods of using a TGF-beta ligand trap to reduce right ventricular systolic pressure in a subject.
    Type: Grant
    Filed: November 21, 2014
    Date of Patent: June 16, 2020
    Assignees: THE BRINGHAM AND WOMEN'S HOSPITAL, INC., ACCELERON PHARMA, INC.
    Inventors: Paul Yu, Asya Grinberg, Dianne S. Sako, Roselyne Castonguay, Rita Steeves, Ravindra Kumar
  • Publication number: 20200157182
    Abstract: In certain aspects, the present disclosure relates to polypeptides comprising a truncated, ligand-binding portion of the extracellular domain of T?RII polypeptide useful to selectively antagonize a T?RII ligand. The disclosure further provides compositions and methods for use in treating or preventing TGF? associated disorders.
    Type: Application
    Filed: January 30, 2020
    Publication date: May 21, 2020
    Inventors: Ravindra Kumar, Asya Grinberg, Dianne S. Sako, Roselyne Castonguay, Rita Steeves
  • Publication number: 20190284257
    Abstract: In certain aspects, the present disclosure relates to polypeptides comprising a truncated, ligand-binding portion of the extracellular domain of T?RII polypeptide useful to selectively antagonize a T?RII ligand. The disclosure further provides compositions and methods for use in treating or preventing TGF? associated disorders.
    Type: Application
    Filed: April 24, 2019
    Publication date: September 19, 2019
    Inventors: Ravindra Kumar, Asya Grinberg, Dianne S. Sako, Roselyne Castonguay, Rita Steeves
  • Patent number: 10316076
    Abstract: In certain aspects, the present disclosure relates to polypeptides comprising a truncated, ligand-binding portion of the extracellular domain of T?RII polypeptide useful to selectively antagonize a T?RII ligand. The disclosure further provides compositions and methods for use in treating or preventing TGF? associated disorders.
    Type: Grant
    Filed: September 25, 2017
    Date of Patent: June 11, 2019
    Assignee: ACCELERON PHARMA INC.
    Inventors: Ravindra Kumar, Asya Grinberg, Dianne S. Sako, Roselyne Castonguay, Rita Steeves
  • Publication number: 20180179261
    Abstract: In certain aspects, the present disclosure relates to polypeptides comprising a truncated, ligand-binding portion of the extracellular domain of T?RII polypeptide useful to selectively antagonize a T?RII ligand. The disclosure further provides compositions and methods for use in treating or preventing TGF? associated disorders.
    Type: Application
    Filed: September 25, 2017
    Publication date: June 28, 2018
    Inventors: Ravindra Kumar, Asya Grinberg, Dianne S. Sako, Roselyne Castonguay, Rita Steeves
  • Patent number: 9809637
    Abstract: In certain aspects, the present disclosure relates to polypeptides comprising a truncated, ligand-binding portion of the extracellular domain of T?RII polypeptide useful to selectively antagonize a T?RII ligand. The disclosure further provides compositions and methods for use in treating or preventing TGF? associated disorders.
    Type: Grant
    Filed: February 16, 2016
    Date of Patent: November 7, 2017
    Assignee: ACCLERON PHARMA INC.
    Inventors: Ravindra Kumar, Asya Grinberg, Dianne S. Sako, Roselyne Castonguay, Rita Steeves
  • Publication number: 20160376341
    Abstract: In certain aspects, the present disclosure relates to polypeptides comprising a truncated, ligand-binding portion of the extracellular domain of T?RII polypeptide useful to selectively antagonize a T?RII ligand. The disclosure further provides compositions and methods for use in treating or preventing TGF? associated disorders.
    Type: Application
    Filed: February 16, 2016
    Publication date: December 29, 2016
    Inventors: Ravindra Kumar, Asya Grinberg, Dianne S. Sako, Roselyne Castonguay, Rita Steeves
  • Publication number: 20160287664
    Abstract: In some aspects, the invention teaches pharmaceutical compositions that include a TGF-beta ligand trap, and methods of using a TGF-beta ligand trap to treat, prevent, or reduce the progression rate of pulmonary hypertension (PH). The invention also provides methods of using a TGF-beta ligand trap to treat, prevent, or reduce the progression rate of a variety of conditions including, but not limited to, pulmonary vascular remodeling, pulmonary fibrosis, right ventricular hypertrophy, diseases associated with excessive TGF-beta signaling, diseases associated with excessive GDF15 signaling, and diseases associated with excessive PAI-1 signaling. The invention further provides methods of using a TGF-beta ligand trap to reduce right ventricular systolic pressure in a subject.
    Type: Application
    Filed: November 21, 2014
    Publication date: October 6, 2016
    Applicants: THE BRIGHAM AND WOMEN'S HOSPITAL, INC., ACCELERON PHARMA INC.
    Inventors: Paul YU, Asya GRINBERG, Dianne S. SAKO, Roselyne CASTONGUAY, Rita STEEVES, Ravindra KUMAR
  • Publication number: 20150056199
    Abstract: In certain aspects, the present disclosure relates to polypeptides comprising a truncated, ligand-binding portion of the extracellular domain of T?RII polypeptide useful to selectively antagonize a T?RII ligand. The disclosure further provides compositions and methods for use in treating or preventing TGF? associated disorders.
    Type: Application
    Filed: August 21, 2014
    Publication date: February 26, 2015
    Inventors: Ravindra Kumar, Asya Grinberg, Dianne S. Sako, Roselyne Castonguay, Rita Steeves
  • Patent number: 8388960
    Abstract: Methods of killing or inhibiting tumors comprising of heterogeneous or mixed cell populations is described. The killing or inhibition of tumors is achieved by selectively targeting a unique ligand suspected of being expressed on a particular cell population to also kill a cell population lacking the unique ligand. These conjugates have therapeutic use as they are delivered to a specific cell population to kill these cells and the cytotoxic drug is released to kill non-targeted cells, thereby eliminating the tumor.
    Type: Grant
    Filed: September 9, 2011
    Date of Patent: March 5, 2013
    Assignee: Immunogen Inc.
    Inventors: Viktor S. Goldmakher, Robert J. Lutz, Ravi V. J. Chari, Yelena V. Kovtun, John M. Lambert, Rita Steeves, Hans K. Erickson, Wayne C. Widdison
  • Patent number: 8137669
    Abstract: Methods of killing or inhibiting tumors comprising of heterogeneous or mixed cell populations is described. The killing or inhibition of tumors is achieved by selectively targeting a unique ligand suspected of being expressed on a particular cell population to also kill a cell population lacking the unique ligand. These conjugates have therapeutic use as they are delivered to a specific cell population to kill these cells and the cytotoxic drug is released to kill non-targeted cells, thereby eliminating the tumor.
    Type: Grant
    Filed: August 5, 2008
    Date of Patent: March 20, 2012
    Assignee: Immunogen, Inc.
    Inventors: Viktor S. Goldmakher, Robert J. Lutz, Ravi V. J. Chari, Yelena V. Kovtun, John M. Lambert, Rita Steeves, Hans K. Erickson
  • Publication number: 20110319612
    Abstract: Methods of killing or inhibiting tumors comprising of heterogeneous or mixed cell populations is described. The killing or inhibition of tumors is achieved by selectively targeting a unique ligand suspected of being expressed on a particular cell population to also kill a cell population lacking the unique ligand. These conjugates have therapeutic use as they are delivered to a specific cell population to kill these cells and the cytotoxic drug is released to kill non-targeted cells, thereby eliminating the tumor.
    Type: Application
    Filed: September 9, 2011
    Publication date: December 29, 2011
    Applicant: IMMUNOGEN INC.
    Inventors: Viktor S. GOLDMAKHER, Robert J. LUTZ, Ravi V.J. CHARI, Yelena V. KOVTUN, John M. LAMBERT, Rita STEEVES, Hans K. ERICKSON
  • Publication number: 20090076263
    Abstract: Methods of killing or inhibiting tumors comprising of heterogeneous or mixed cell populations is described. The killing or inhibition of tumors is achieved by selectively targeting a unique ligand suspected of being expressed on a particular cell population to also kill a cell population lacking the unique ligand. These conjugates have therapeutic use as they are delivered to a specific cell population to kill these cells and the cytotoxic drug is released to kill non-targeted cells, thereby eliminating the tumor.
    Type: Application
    Filed: August 5, 2008
    Publication date: March 19, 2009
    Applicant: ImmunoGen Inc.
    Inventors: Viktor S. Goldmakher, Robert J. Lutz, Ravi V.J. Chari, Yelena V. Kovtun, John M. Lambert, Rita Steeves, Hans K. Erickson